CD274 and non-small cell lung carcinoma: In recent years, immune checkpoint inhibitors (ICIs) that target programmed death 1 (PD-1) or its ligand (PD-L1) has significantly improved the prognosis of advanced non-small cell lung cancer (NSCLC) compared with standard chemotherapy.